GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stoke Therapeutics Inc (STU:0GT) » Definitions » Institutional Ownership

Stoke Therapeutics (STU:0GT) Institutional Ownership : 18.10% (As of Jun. 10, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Stoke Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Stoke Therapeutics's institutional ownership is 18.10%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Stoke Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Stoke Therapeutics's Float Percentage Of Total Shares Outstanding is 66.44%.


Stoke Therapeutics Institutional Ownership Historical Data

The historical data trend for Stoke Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stoke Therapeutics Institutional Ownership Chart

Stoke Therapeutics Historical Data

The historical data trend for Stoke Therapeutics can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 21.68 20.46 18.77 17.02 15.80 15.75 15.67 19.42 18.00 18.10

Stoke Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Stoke Therapeutics (STU:0GT) Business Description

Traded in Other Exchanges
Address
45 Wiggins Avenue, Bedford, MA, USA, 01730
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company primarily operates in the U.S.

Stoke Therapeutics (STU:0GT) Headlines

No Headlines